查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1701345

化疗嗜中性白血球低下症治疗市场规模、份额、趋势分析报告：按疗法、药物、给药途径、通路、地区和细分市场进行预测，2025 年至 2030 年

Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 195 Pages | 商品交期: 2-10个工作天内

价格

化疗引起的嗜中性白血球低下症(CIN) 治疗市场的成长和趋势

根据Grand View Research, Inc.的最新报告，全球化疗引起的嗜中性白血球低下症治疗市场预计到2030年将达到15.1亿美元，2025年至2030年期间的复合年增长率为-0.48%。

这种下降可能是由于多种因素造成的，包括标靶癌症疗法和免疫疗法的采用率增加，与传统化疗相比，这些疗法降低了化疗引起的嗜中性白血球低下症的发生率。随着精准医疗的进步，肿瘤学家越来越多地转向最大限度减少骨髓抑製作用的治疗方法，从而减少对 CIN 治疗的需求。然而，居家医疗治疗方法和自我治疗的兴起也为製药公司提供了开髮用户友好型配方以提高患者便利性的机会。

化疗引起的嗜中性白血球低下症是癌症治疗的一个严重副作用，对接受化疗的患者构成重大风险。随着癌症发病率不断上升，对有效 CIN 治疗的需求正在推动医疗保健领域的显着增长。开发人员正在利用治疗方法进步、新药开发和改进的患者照护解决方案来解决这一重大疾病。市场对生长因子、抗生素、抗真菌药物和其他支持疗法的投资正在增加，以确保更好地管理 CIN 并减少相关併发症。

为了有效对抗 CIN，生长因子在刺激白血球生成和降低儿童感染疾病风险方面发挥关键作用。颗粒细胞增生因子(G-CSF) 是主要的治疗选择，可促进嗜中性白血球恢復并最大限度地减少化疗延迟。安进公司 (Amgen Inc.)、山德士 (Sandoz)、梯瓦製药工业有限公司 (Teva Pharmaceutical Industries Ltd.)、Coherus BioSciences、Viatris Inc. 和 Biocon Biologics Inc. 等主要製药公司处于 G-CSF 开发的前沿。

Filgrastim是一种广泛使用的 G-CSF 重组形式，可促进嗜中性白血球的恢復。长效非格Filgrastim，Pegfilgrastim，可以减少给药频率，而Pegfilgrastim已被证实可以提供持续的嗜中性白血球刺激。 Efrapegrastim 是一种新型长效 G-CSF，可有效预防 CIN，而 efvemarenograstim alfa 是一种正在开发的增强嗜中性白血球支持的下一代疗法。此外，粒细胞巨噬细胞集落刺激因子 (GM-CSF) 在嗜中性白血球恢復方面具有治疗潜力。辉瑞公司、Spectrum Pharmaceuticals, Inc.、Evive Biotech 和 G1 Therapeutics, Inc. 等主要市场参与企业正积极投资研发，以提高这些治疗的疗效。

然而，儘管使用了生长因子，CIN 患者仍然容易受到细菌和真菌感染，因此使用预防性和治疗性抗生素至关重要。预防性抗生素在预防高风险患者感染方面发挥重要作用，而如果发生感染疾病则使用治疗性抗生素。同样，抗真菌药物有助于对抗机会性感染疾病，确保全面的患者照护。总的来说，这些治疗方法形成了一个多层次的防御系统，以抵御 CIN 带来的风险。预防性抗生素作为预防措施，可降低嗜中性白血球低下症患者的感染率，而治疗性抗生素则有助于对抗因免疫系统减弱而引起的细菌感染疾病。抗真菌药物还可以增强对侵袭性真菌感染疾病的防御，这种感染对于接受化疗的患者来说可能是危及生命的。

除了这些传统的治疗方案外，粒细胞输注和免疫调节剂等较新的治疗方法也受到关注，成为治疗严重嗜中性白血球低下症的潜在解决方案。持续的研究和创新有望提高这些治疗方法的有效性和可近性，进一步加强市场环境。 CIN 治疗市场分为品牌药物和生物相似药。虽然品牌药物因其既定的疗效而继续占据主导地位，但生物相似药因其成本效益和日益普及而迅速普及。随着监管部门核准的扩大和医疗服务可及性的改善，生物相似药的选择越来越广泛，使更多患者能够从先进的疗法中受益，而无需承担昂贵的品牌药物的经济负担。

随着新药的开发，药物输送治疗方法也不断发展。肠外给药仍是 CIN 治疗的黄金标准，建议透过静脉注射G-CSF 和抗生素来获得快速有效的结果。然而，口服预防性抗生素和免疫调节剂在门诊环境中提供了便利，并且越来越受欢迎。这些管理上的变化与整个医疗保健领域的趋势一致，即改善患者的就医机会并减少对医院进行慢性病管理的依赖。

随着全球癌症负担不断增加，CIN治疗市场预计将大幅扩大。生物相似药的日益普及、药物开发的持续进步以及创新治疗方法的持续研究正在共同塑造 CIN 管理的未来。随着认识的提高、治疗通讯协定的改进以及对支持性护理的投入增加，CIN 治疗的未来可能会取得重大进展。这些发展不仅改善了患者的治疗效果，而且促进了全球医疗保健解决方案的整体进步。

化疗嗜中性白血球低下症治疗市场报告重点

  • 根据治疗方法，生长因子部分在 2024 年占据了市场主导地位。该部分的主导地位可归因于其经过验证的功效、在癌症治疗方案中的广泛采用以及生物仿製药的持续进步。
  • 2024 年，生物相似药在药物类型领域占据市场领先地位，这得益于监管部门核准的不断增加、成本效益的提高以及医疗保健提供者的日益普及。
  • 根据给药途径，2024 年肠外给药占市场主导地位。注射剂型，尤其是静脉注射和皮下注射 G-CSF，由于与口服给药相比起效更快、生物有效性更高，仍然是主要的给药方式。
  • 从分销管道来看，由于医院化疗的普及率较高，医院药局在 2024 年占据了最大的市场占有率。医院药局是 CIN 治疗的主要来源，确保关键药物的即时供应和管理。
  • 由于完善的医疗基础设施、较高的癌症意识和先进的治疗选择，北美在 CIN 治疗市场处于领先地位。该地区对研究和创新的高度重视进一步推动了市场成长。

目录

第一章调查方法与范围

第二章执行摘要

第三章化疗嗜中性白血球低下症治疗市场变数、趋势和范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 定价分析

第四章化疗引起的嗜中性白血球低下症治疗市场：治疗业务分析

  • 2024年和2030年的治疗市场占有率
  • 治疗细分仪表板
  • 市场规模、预测与趋势分析（按治疗，2018-2030 年）
  • 生长因子
  • 抗生素
  • 抗真菌剂
  • 其他的

第五章化疗嗜中性白血球低下症治疗市场：製药业务分析

  • 2024年及2030年的医药市场占有率
  • 药品细分仪表板
  • 市场规模、预测与趋势分析（按药物，2018-2030 年）
  • 品牌药品
  • 生物相似药

第六章化疗嗜中性白血球低下症治疗市场：给药途径业务分析

  • 2024 年及 2030 年给药途径市场占有率
  • 给药途径细分仪表板
  • 按管理路线分類的市场规模、预测和趋势分析（2018-2030 年）
  • 肠外
  • 口服

第七章化疗引起的嗜中性白血球低下症治疗市场：分销通路业务分析

  • 2024年及2030年分销通路市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院药房
  • 零售药局
  • 网路药局

第八章化疗嗜中性白血球低下症治疗市场：按地区估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章竞争格局

  • 参与者概述
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Amgen Inc.
    • Sandoz
    • Teva Pharmaceutical Industries Ltd
    • Coherus BioSciences Inc.
    • Coherus BioSciences Inc.
    • Viatris Inc.
    • Biocon Biologics Inc.
    • Pfizer Inc.
    • Spectrum Pharmaceuticals, Inc.
    • Evive BIoTech
    • G1 Therapeutics, Inc.
Product Code: GVR-4-68040-198-8

Chemotherapy-induced Neutropenia Treatment Market Growth & Trends:

The global chemotherapy-induced neutropenia treatment market is anticipated to reach USD 1.51 billion by 2030 and is expected to decline at a CAGR of -0.48% from 2025 to 2030, according to a new report by Grand View Research, Inc. This decline can be attributed to multiple factors, including the growing adoption of targeted cancer therapies and immunotherapies, which reduce the incidence of chemotherapy-induced neutropenia (CIN) compared to traditional chemotherapy. As precision medicine advances, oncologists are increasingly shifting towards treatment modalities that minimize myelosuppressive effects, thereby reducing the demand for CIN treatments. However, the rise of home healthcare and self-administrable therapies also presents an opportunity for pharmaceutical companies to develop user-friendly formulations that improve patient convenience.

Chemotherapy-Induced Neutropenia (CIN), a severe side effect of cancer treatment, poses significant risks for patients undergoing chemotherapy. As the prevalence of cancer cases continues to rise, the demand for effective CIN treatments is driving substantial growth in the healthcare sector. Businesses are capitalizing on advancements in treatment modalities, novel drug developments, and improved patient care solutions to address this critical condition. The market is witnessing increased investments in growth factors, antibiotics, antifungal agents, and other supportive therapies, ensuring better management of CIN and reducing associated complications.

To combat CIN effectively, growth factors play a vital role in stimulating white blood cell production, reducing the risk of infections in affected patients. Granulocyte Colony-Stimulating Factors (G-CSFs) are the primary treatment option, enhancing neutrophil recovery and minimizing chemotherapy delays. Leading pharmaceutical companies such as Amgen Inc., Sandoz, Teva Pharmaceutical Industries Ltd., Coherus BioSciences, Viatris Inc., and Biocon Biologics Inc. are at the forefront of G-CSF development.

Filgrastim is a widely used recombinant G-CSF that accelerates neutrophil recovery. Pegfilgrastim, a longer-acting version of Filgrastim, reduces the frequency of administration, while Lipegfilgrastim offers sustained neutrophil stimulation. Eflapegrastim is a novel, long-acting G-CSF providing effective prophylaxis against CIN, and Efbemalenograstim alfa is a next-generation therapy under development for enhanced neutrophil support. Additionally, Granulocyte-Macrophage Colony-Stimulating Factors (GM-CSFs) are expanding the therapeutic potential in neutrophil recovery. Key market players, including Pfizer Inc., Spectrum Pharmaceuticals, Inc., Evive Biotech, and G1 Therapeutics, Inc., are actively investing in research and development to improve the efficacy of these treatments.

However, even with the use of growth factors, CIN patients remain highly susceptible to bacterial and fungal infections, making the use of prophylactic and therapeutic antibiotics crucial. Prophylactic antibiotics play a key role in preventing infections in high-risk patients, while therapeutic antibiotics are administered when infections develop. Similarly, antifungal agents help combat opportunistic infections, ensuring comprehensive patient care. These treatments collectively form a multi-layered defense system against the risks posed by CIN. Prophylactic antibiotics serve as a preventive measure to reduce infection rates in neutropenic patients, whereas therapeutic antibiotics help manage bacterial infections that arise due to the weakened immune system. Meanwhile, antifungal agents provide an added layer of protection against invasive fungal infections, which can be life-threatening for patients undergoing chemotherapy.

In addition to these conventional treatment options, emerging therapies such as granulocyte transfusions and immunomodulatory agents are gaining attention as potential solutions for severe cases of neutropenia. Ongoing research and innovation are expected to enhance the effectiveness and accessibility of these treatment options, further strengthening the market landscape. The CIN treatment market is divided into branded drugs and biosimilars. Branded drugs continue to dominate due to their established efficacy, but biosimilars are rapidly gaining traction due to their cost-effectiveness and increasing adoption. As regulatory approvals expand and healthcare accessibility improves, biosimilar options are becoming more widely available, allowing more patients to benefit from advanced therapies without the financial burden of high-priced branded drugs.

Along with the development of new drug options, treatment delivery methods are also evolving. Parenteral administration remains the gold standard for CIN management, with intravenous (IV) and subcutaneous (SC) routes being preferred for G-CSFs and antibiotics to ensure rapid and effective results. However, oral options for prophylactic antibiotics and immunomodulatory agents are gaining popularity, offering greater convenience for outpatient care. This shift in administration methods aligns with the broader healthcare trend of enhancing patient accessibility and reducing hospital dependency for chronic care management.

As the burden of cancer continues to grow worldwide, the CIN treatment market is poised for substantial expansion. The increasing adoption of biosimilars, continuous advancements in drug development, and ongoing research into innovative therapies are collectively shaping the future of CIN management. With enhanced awareness, improved treatment protocols, and growing investment in supportive care, the future of CIN treatment is set to witness significant progress. These developments not only ensure better patient outcomes but also contribute to the overall advancement of global healthcare solutions.

Chemotherapy-induced Neutropenia Treatment Market Report Highlights:

  • On the basis of treatment, the growth factors segment dominated the market in 2024. The segment's dominance is attributable to its proven efficacy, widespread adoption in cancer treatment protocols, and continuous advancements in biosimilars.
  • Biosimilars led the drug type segment in market in 2024, driven by increasing regulatory approvals, cost-effectiveness, and growing adoption by healthcare providers..
  • On the basis of the route of administration, the parenteral segment dominated the market in 2024. Injectable formulations, particularly intravenous and subcutaneous G-CSFs, remain the primary mode of administration due to the rapid onset of their action and higher bioavailability compared to oral alternatives.
  • On the basis of distribution channel, the hospital pharmacies segment held the largest market share in 2024, driven by the high volume of chemotherapy conducted in hospital settings. Hospital pharmacies are the primary source of CIN treatment drugs, ensuring immediate availability and administration of critical medications
  • North America led the CIN treatment market, attributed to factors such as a well-established healthcare infrastructure, high awareness of cancer, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Drug
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Distribution Channel & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Chemotherapy-Induced Neutropenia (CIN) Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
      • 3.3.3.1. Phase 1
      • 3.3.3.2. Phase 2
      • 3.3.3.3. Phase 3
    • 3.3.4. Pricing Analysis

Chapter 4. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 4.4. Growth Factors
    • 4.4.1. Growth Factors Market, 2018 - 2030 (USD Million)
  • 4.5. Antibiotics
    • 4.5.1. Antibiotics Market, 2018 - 2030 (USD Million)
  • 4.6. Antifungal Agents
    • 4.6.1. Antifungal Agents Market, 2018 - 2030 (USD Million)
  • 4.7. Other Treatments
    • 4.7.1. Other Treatments Market, 2018 - 2030 (USD Million)

Chapter 5. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Drug Business Analysis

  • 5.1. Drug Market Share, 2024 & 2030
  • 5.2. Drug Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug, 2018 to 2030 (USD Million)
  • 5.4. Branded Drugs
    • 5.4.1. Branded Drugs Market, 2018 - 2030 (USD Million)
  • 5.5. Biosimilars
    • 5.5.1. Biosimilars Market, 2018 - 2030 (USD Million)

Chapter 6. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2030
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Parenteral
    • 6.4.1. Parenteral Market, 2018 - 2030 (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral Market, 2018 - 2030 (USD Million)

Chapter 7. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. Uk Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. China Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Amgen Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Sandoz
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Teva Pharmaceutical Industries Ltd
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Coherus BioSciences Inc.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Coherus BioSciences Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Viatris Inc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Biocon Biologics Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Pfizer Inc.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Spectrum Pharmaceuticals, Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Evive Biotech
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. G1 Therapeutics, Inc.
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 5 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 6 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 10 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 11 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 12 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 14 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 15 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 16 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 18 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 19 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 20 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 22 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 23 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 26 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 27 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 28 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 29 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 31 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 32 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 33 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 35 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 36 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 37 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 39 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 40 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 41 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 43 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 44 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 45 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 48 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 49 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 52 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 53 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 56 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 57 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 60 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 61 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 69 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 70 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 71 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 72 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 73 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 74 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 77 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 78 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 79 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 81 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 82 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 83 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 85 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 86 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 87 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 89 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 90 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 91 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 93 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 94 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 95 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 96 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 97 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 98 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 99 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 100 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 101 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 102 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 103 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 104 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 109 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 110 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 111 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 112 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 113 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 117 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 118 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 119 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 120 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 121 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 124 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 125 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Chemotherapy-induced neutropenia (CIN) treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Treatment and Drug snapshot
  • Fig. 11 Route of administration and distribution channel snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Parent market value, 2024 (USD billion)
  • Fig. 14 Market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTLE analysis
  • Fig. 17 Chemotherapy-induced neutropenia (CIN) treatment market: Treatment outlook and key takeaways
  • Fig. 18 Chemotherapy-induced neutropenia (CIN) treatment market: Treatment movement analysis
  • Fig. 19 Growth factors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Antifungal agents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Other treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Chemotherapy-induced neutropenia (CIN) treatment market: Drug outlook and key takeaways
  • Fig. 24 Chemotherapy-induced neutropenia (CIN) treatment market: Drug movement analysis
  • Fig. 25 Branded drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Biosimilar market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Chemotherapy-induced neutropenia (CIN) treatment market: Route of administration outlook and key takeaways
  • Fig. 28 Chemotherapy-induced neutropenia (CIN) treatment market: Route of administration movement analysis
  • Fig. 29 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Chemotherapy-induced neutropenia (CIN) treatment market: Distribution channel market outlook and key takeaways
  • Fig. 32 Chemotherapy-induced neutropenia (CIN) treatment market: Distribution channel market movement analysis
  • Fig. 33 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Chemotherapy-induced neutropenia (CIN) treatment market revenue, by region, 2024 & 2030 (USD Million)
  • Fig. 37 Regional marketplace: Key takeaways
  • Fig. 38 North America chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 U.S. chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Cancer incidence, 2022 - 2045
  • Fig. 42 U.S. healthcare system: money flow
  • Fig. 43 Key country dynamics
  • Fig. 44 Canada chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Cancer incidence, 2022 - 2045
  • Fig. 46 Key country dynamics
  • Fig. 47 Mexico chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Cancer incidence, 2022 - 2045
  • Fig. 49 Regulatory framework
  • Fig. 50 Europe chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 UK chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Cancer incidence, 2022 - 2045
  • Fig. 54 Key country dynamics
  • Fig. 55 Germany chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Cancer incidence, 2022 - 2045
  • Fig. 57 Exclusivity formula
  • Fig. 58 Germany insurance coverage
  • Fig. 59 Key country dynamics
  • Fig. 60 France chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Cancer incidence, 2022 - 2045
  • Fig. 62 Key country dynamics
  • Fig. 63 Italy chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Cancer incidence, 2022 - 2045
  • Fig. 65 Key country dynamics
  • Fig. 66 Spain chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Cancer incidence, 2022 - 2045
  • Fig. 68 Key country dynamics
  • Fig. 69 Denmark chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Cancer Incidence, 2022 - 2045
  • Fig. 71 Key country dynamics
  • Fig. 72 Sweden chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Cancer incidence 2022 - 2045
  • Fig. 74 Key country dynamics
  • Fig. 75 Norway chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Cancer incidence, 2022 - 2045
  • Fig. 77 Rest of Europe chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Asia Pacific chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Japan chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Cancer incidence, 2022 - 2045
  • Fig. 82 Japan pharmaceutical registration
  • Fig. 83 Key country dynamics
  • Fig. 84 China chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Cancer incidence, 2022 - 2045
  • Fig. 86 Regulatory details: China
  • Fig. 87 Key country dynamics
  • Fig. 88 India chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 89 Cancer incidence, 2018 - 2030
  • Fig. 90 Key country dynamics
  • Fig. 91 Australia chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 Cancer incidence, 2018 - 2030
  • Fig. 93 Key country dynamics
  • Fig. 94 Thailand chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 95 Cancer incidence, 2018 - 2030
  • Fig. 96 Key country dynamics
  • Fig. 97 South Korea chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 98 Cancer incidence, 2018 - 2030
  • Fig. 99 Rest of Asia Pacific chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 100 Latin America chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 Brazil chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Cancer incidence, 2018 - 2030
  • Fig. 104 Key country dynamics
  • Fig. 105 Argentina chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Cancer incidence, 2018 - 2030
  • Fig. 107 Rest of Latin America chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 MEA chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 South Africa chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Cancer incidence, 2018 - 2030
  • Fig. 112 Key country dynamics
  • Fig. 113 Saudi Arabia chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 114 Cancer incidence, 2018 - 2030
  • Fig. 115 Key country dynamics
  • Fig. 116 UAE chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 117 Cancer incidence, 2018 - 2030
  • Fig. 118 Key country dynamics
  • Fig. 119 Kuwait chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 120 Cancer incidence, 2018 - 2030
  • Fig. 121 Rest of MEA chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 122 Company/competition categorization
  • Fig. 123 Strategy mapping